BIODLINK-B has released a voluntary announcement addressing recent unusual share price movements, aiming to convey a positive message to the market and investors.
The announcement clearly states that the company's operations are robust, its fundamentals are sound, and there is no undisclosed material adverse information. It also provides an update on the post-merger integration with WuXi XDC and outlines the future growth path.
Reaffirming Operational Stability and Transparency
The company's board confirms there are no undisclosed material adverse developments, operational changes, or risk events, and that operations are proceeding normally.
BIODLINK-B emphasizes its strict adherence to the disclosure obligations under the Hong Kong Stock Exchange's listing rules to ensure a fair and transparent market.
Post-Merger Integration Progressing Smoothly
The merger with WuXi XDC, a significant milestone, was successfully completed by the end of March 2026. Integration efforts across business operations, systems, and teams are now advancing steadily and in an orderly manner.
Management reports that integration is on track, synergistic benefits are gradually materializing, and a solid foundation has been laid for enhancing operational efficiency and market competitiveness.
Leveraging WuXi XDC's globally leading ADC platform, the company is undergoing comprehensive upgrades in quality control systems, project execution track records, and the expansion of global client resources.
This enhances its capability to undertake more complex and larger-scale ADC projects, significantly boosting its overall competitiveness.
Securing Future Growth Through a Connected Transaction Agreement
To ensure business growth certainty and sustainability, BIODLINK-B has entered into a continuing connected transaction agreement with WuXi XDC, subject to approval by an extraordinary general meeting.
Under this arrangement, the company will secure a stable volume of Antibody-Drug Conjugate CDMO outsourcing business over the next three years, providing clear and direct momentum for growth.
Favorable Industry Tailwinds Support Long-Term Prospects
Data presented at the 2026 American Society of Clinical Oncology Annual Meeting indicates the ADC industry is transitioning from scale expansion to high-quality development, with structural opportunities emerging.
Key trends include a more than 35% increase in Phase III clinical trials, rapid expansion of registration-stage pipelines, and Chinese companies' share of global ADC development rising from 35% to 50%.
Breakthroughs, such as confirming ADC+immunotherapy regimens in first-line settings and positive data for novel bispecific ADCs, signal ADC's evolution into a core backbone of combination cancer therapies, driving sustained growth in CDMO outsourcing demand.
Target diversity has expanded to over 50, with promising preclinical data for novel targets like GPC3 and 5T4 enriching the next generation of ADC pipelines.
Against this industry backdrop and supported by the WuXi XDC platform, BIODLINK-B maintains solid fundamentals, a sufficient project pipeline, and an optimising client structure, pointing to a positive and promising outlook.
Strategic Focus and Forward Outlook
Looking ahead, BIODLINK-B will focus its resources on several key areas: deepening business synergy and integration with WuXi XDC; strengthening core operations and enhancing global service quality and delivery standards; and actively expanding its global client base to drive performance growth and create shareholder value.
The board reiterates its commitment to safeguarding the interests of the company and its shareholders and to delivering long-term, sustainable value returns.
As a key player in the ADC CDMO sector, BIODLINK-B aims not only to serve current market needs but also to collaborate with WuXi XDC in building a platform for next-generation ADC technology R&D and production.
With the ongoing favorable industry cycle, deep synergy with its partner, and strong execution capabilities, the company is positioned for expansive future growth.